Followers | 209 |
Posts | 20834 |
Boards Moderated | 3 |
Alias Born | 01/09/2019 |
Friday, July 19, 2024 11:20:33 AM
Everything I say is my educated opinion and is NOT investment advice
Recent PSNL News
- Personalis to Announce Third Quarter 2024 Financial Results • Business Wire • 10/23/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 09:28:28 PM
- ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test • Business Wire • 09/16/2024 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/12/2024 04:15:07 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/30/2024 08:43:07 PM
- Personalis to Participate at Upcoming Investor Conferences • Business Wire • 08/22/2024 08:01:00 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/20/2024 08:27:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 08:17:55 PM
- Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 08/19/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 01:25:01 PM
- Personalis and Tempus Announce Expanded Collaboration • Business Wire • 08/16/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 08:35:56 PM
- Personalis Reports Second Quarter 2024 Financial Results • Business Wire • 08/07/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 08:00:09 PM
- Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12% • GlobeNewswire Inc. • 08/06/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 09:16:00 PM
- Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference • Business Wire • 07/31/2024 08:01:00 PM
- Personalis to Announce Second Quarter 2024 Financial Results • Business Wire • 07/24/2024 08:01:00 PM
- Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing • GlobeNewswire Inc. • 07/11/2024 01:00:00 PM
- Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference • Business Wire • 06/18/2024 08:01:00 PM
- Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call • Business Wire • 06/13/2024 12:00:00 PM
- ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring • Business Wire • 06/04/2024 08:05:00 PM
- Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus • Business Wire • 05/31/2024 01:05:00 PM
- Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024 • Business Wire • 05/22/2024 01:05:00 PM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM